November 22, 2024

The Catholic Transcript

Complete News World

Study indicates Coronavac’s high protection against dangerous conditions caused by the delta variable – science

Study indicates Coronavac’s high protection against dangerous conditions caused by the delta variable – science

Protection for severe cases of COVID-19 Variable delta induced up to 100% among inactivated virus vaccines, including Coronavac. This is what the Center for Disease Control and Prevention (CDC Chinese) and the College of Public Health in Guandong Province, In China.

In the case of delta-induced pneumonia, protection ranged from 69.5% to 77.7%, according to the survey.

The article has been submitted for publication in the scientific journal scalpel, the most famous in the medical field, and published on the official preprint page of the journal (articles without peer review).

In addition to Coronavac, the Chinese state-owned Sinopharm and Biokangtai vaccines were also analyzed, although the latter did not show results due to the low number of injections applied in the country.

Coronavac analysis

for results, Researchers collected data from 10,813 confirmed cases of Covid-19 or from close contacts, such as people who live in the same household with an infected person or who live in the same public place as that person, up to four days before symptoms appear.

During the study period, the variable was identified as b 1.617.2, arrived in the county and was linked to the outbreak, with at least 167 confirmed cases, from May 21 to June 18. Data was collected until June 23, when monitoring of those who had contact with confirmed cases was completed.

Of the individuals covered by the survey, 54.4% were not vaccinated, 28.95% received at least one dose of the vaccine and 14.6% received both doses. Most of the participants received at least one or two injections of Coronavac (51.3% and 58.3%, respectively).

See also  Increases the number of Covid sequences in SUS Care - News

102 cases of pneumonia caused by Covid-19 have been recorded., including 85 in unvaccinated people, 12 in individuals who received at least one dose of vaccines and only 5 in people with a full vaccination schedule.

The efficacy of two doses of the vaccine was 77.7%, and decreased slightly to 69.5% when adjusted for other factors such as occupation, gender, age or place of residence.

Ineffectiveness in just one dose

In subjects who received only one dose of the immunizing agent, the analysis was not statistically significant, that is, the first dose was not sufficient to prevent cases of pneumonia in these patients.

Regarding the severe case of Covid-19, 19 cases were recorded, all in the unvaccinated group, indicating 100% efficacy of the vaccines. However, since the number of cases is relatively low, it is necessary to wait for more studies to confirm this value.